Contrast agent developer Advanced Magnetics of Cambridge, MA, has filed a supplemental new drug application (NDA) with the Food and Drug Administration covering new applications for its Feridex I.V. MRI liver agent. The company is seeking the FDA's approval to market Feridex for use in distinguishing benign from malignant liver lesions.
Feridex was originally approved in August 1996, and is marketed in the U.S. by Berlex Laboratories of Wayne, NJ.
By AuntMinnie.com staff writersDecember 28, 2000
Related Reading
Advanced Magnetics posts lower Q4 results, November 27, 2000
Advanced Magnetics agent gets approvable letter, June 22, 2000
Advanced Magnetics trims loss in Q3, July 24, 2000
Copyright © 2000 AuntMinnie.com